Redwood Pharma enters into agreement with CRO for clinical trial
Redwood Pharma AB (publ) has contracted the Swiss contract research organization (CRO) CROss Alliance® for the management of a clinical phase II trial in patients with chronic dry eye disease. The clinical trial will be performed in Europe where CROss Alliance is well-established and has earlier successfully executed several studies within ophthalmology.The agreement with Cross Alliance represents an important step in the development of RP101, Redwood Pharma’s new drug candidate for the treatment of dry eye disease in postmenopausal women. After a thorough selection process, the Company has